Toll-like receptor expression and activation in mice with experimental dry eye.
Redfern. Rachel L RL; Patel. Nimesh N; Hanlon. Samuel S; Farley. William W; Gondo. Margaret M; Pflugfelder. Stephen C SC; McDermott. Alison M AM
Key Findings
- Dry‑eye mice show higher TLR2, TLR3, TLR4, and TLR9 levels in eye tissues
- The LL‑37 equivalent (CRAMP) is reduced in dry‑eye mice
- Applying TLR agonists to the eye worsens inflammation, thins the cornea, and causes epithelial loss
- Human dry‑eye patients also show altered TLR and LL‑37 expression
Practical Outcomes
- For biohackers, this study suggests that stimulating TLRs on the eye surface is likely harmful and that low LL‑37 levels are linked to dry‑eye inflammation. There’s no clear protocol to boost LL‑37 for eye health, so focus on proven dry‑eye treatments rather than experimental TLR‑activating compounds.
Summary
In mice with dry eye, the eye’s immune sensors (TLRs) become more active while the natural antimicrobial peptide LL‑37 (called CRAMP in mice) drops. Adding TLR‑activating substances to the eye makes the cornea swell, lose cells, and get thinner, especially if the surface is already scratched. Similar changes in TLRs and LL‑37 were seen in people with dry‑eye symptoms.
Abstract
To investigate the expression and/or function of toll-like receptors (TLRs) and antimicrobial peptides (AMPs) in dry eye inflammation. Experimental dry eye (EDE) was induced in C57BL/6 mice and TLR mRNA and protein expression were determined at the ocular surface and lacrimal gland. TLR agonist cocktail was applied to the ocular surface in untreated (UT), corneal scratched, and EDE mice. The corneal expression of cathelin-related antimicrobial peptide (CRAMP; human LL-37 orthologue), and mouse beta defensin (mBD)-3 and -4 (human BD-2 orthologue) was compared. LL-37, hBD-2, TLR4, 5, and TLR9 mRNA expression was examined in patients with dysfunctional tear syndrome (DTS) via conjunctival impression cytology. Murine central corneal thickness (CCT) and inflammatory cell recruitment into the stroma was determined by in vivo imaging. EDE upregulated TLR2-4 and 9 mRNA expression in the palpebral conjunctiva and with the exception of TLR4, a similar expression, occurred in the corneal epithelium. TLR2 and 5 were upregulated in lacrimal gland and overall, there was a corresponding change in TLR protein. EDE decreased CRAMP mRNA and protein. hBD-2 and TLR9 expression were modulated in DTS subjects. Topical TLR agonist increased inflammatory cells recruitment and CCT in mice with a cornea scratch. In EDE, TLR agonist treatment downregulated corneal mBD-4 protein caused corneal epithelial loss, and stromal ulceration resulting in decreased CCT. DTS modulates the expression of TLR and CRAMP and topical application of TLR agonists in EDE mice resulted in corneal epithelial loss and thinning. These results suggest that TLRs are involved in DTS inflammation.
Study Information
pubmed
2013
2013-02-28T00:00:00.000Z
10.1167/iovs.12-10739
64
41